Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24255876 | 0.74 | KDM4E (0.45) | KDM4EALDH1A1BTKCSNK2A2CSNK2B | |
| SCHEMBL92519 | 0.73 | — | — | |
| SCHEMBL23225408 | 0.68 | GLA (0.34) | TSHRGLA | |
| SCHEMBL24058694 | 0.68 | — | — | |
| SCHEMBL28195765 | 0.65 | — | — | |
| SCHEMBL25131028 | 0.64 | TSHR (0.57) | TSHRKDM4EALDH1A1BTKHTT | |
| SCHEMBL16706274 | 0.62 | CSNK2A2 (0.35) | KDM4EALDH1A1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9900356 | 0.61 | KDM4E (0.38) | KDM4EALDH1A1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL12569187 | 0.61 | GAA (0.34) | KDM4EALDH1A1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL8471071 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752639-B2 | Bridged bicyclic inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190092783-A1 | BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. (US) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752639-B2 | Bridged bicyclic inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | TSHR 4645/4885KDM4E 82/4885ALDH1A1 3453/4885 |
| US-20190092783-A1 | BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE | MLLT1, MEN1, BMI1 | TSHR 4704/4885KDM4E 179/4885ALDH1A1 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.